After comparing the clinicopathological parameters with the expression of IGLL5 by the Wilcoxon rank‐sum test, we found that the expression of IGLL5 increased with Fuhrman grade (G1–G4), clinical stage (stage I–IV), tumor size (T1–T3) and the number of lymph node metastases (P < 0.05), whereas the differences in sex and distant metastases were not statistically significant (Fig. 6D–I). This evidence concerns the gene IGLL5 and neoplasm.